Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Expert Rev Respir Med. 2019 Feb 15;13(5):407–415. doi: 10.1080/17476348.2019.1577732

Table 1:

Randomized Controlled Trials of Positive Airway Pressure Therapy in Stable Patients with COPD at home

Study Hypercapnia threshold * Actual PaCO2 Age FEV1 (% pred.) Device Pressures (cm H2O) Pressure assist Duration (months)
Casanova 2000 None 52 ± 8.4 66 ± 5 30% Bilevel PAP 12 / 4 8 12
Clini 2002 > 50 54.8 ± 4.5 65 ± 14 29% Bilevel PAP 14 / 2 12 24
Xiang 2007 > 55 Unknown Unknown Unknown Unknown Unknown Unknown 24
McEvoy 2009 > 46 53.5 ± 2.4 68 ± 1.7 24% Bilevel PAP 12.9 / 5.1 7.8 26
Struik 2014 None 58.5 ± 9.0 63.7 ± 8.2 25.6% Bilevel PAP (S/T mode) 19.2/14.8 4.4 12
Kohnlein 2014 > 51.9 58.1 ± 5.6 63.2 ± 8.0 26.7% Home ventilator 21.6 / 4.8 (back-up rate 16) 16.8 12
Zhou 2017 > 50 None 67 ± 7 25.5% Bilevel PAP 17.8 / 4.2 13.6 3
Murphy 2017 > 53 59 ± 7 67 ± 10 23.5% Home ventilator 24 / 4 (back-up rate 14) 20 12

PaCO2 = partial pressure of arterial CO2 level (mmHg); FEV1 = Forced expiratory volume in 1 second; % pred. = Percent predicted; cm H2O = centimeters of water; ± standard deviation; Bilevel PAP = bilevel positive airway pressure.

*

mmHg of PaCO2

HHS Vulnerability Disclosure